No Data
No Data
Stifel Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $150
Stifel analyst Bradley Canino maintains $Blueprint Medicines(BPMC.US)$ with a buy rating, and maintains the target price at $150.According to TipRanks data, the analyst has a success rate of 53.9%
Stifel Nicolaus Remains a Buy on Blueprint Medicines (BPMC)
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
Oppenheimer's Best SMID-cap Ideas: AI, Health, Obesity Drugs, and More
Express News | Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $115
Blueprint Medicines (BPMC) Receives a Hold From Morgan Stanley
No Data